Walgreens is closing about 1,200 of its 8,500 American stores by 2027, and the company making the most of that retreat isn't doing anything dramatic to earn it. CVS is simply waiting nearby.

This is a consolidation story playing out one strip mall at a time, and most of the people affected will only notice it when they pull into a dark parking lot and see a handwritten sign telling them their prescriptions moved down the road.

How a 124-year-old chain ends up here

In August 2025, Walgreens completed a $10 billion sale to private equity firm Sycamore Partners, taking the chain private for the first time in its history. A new CEO, Mike Motz, replaced Tim Wentworth, who stayed on as a director. John Lederer, a senior Sycamore advisor, became executive chairman.

Going private removed Walgreens from Wall Street's daily scrutiny. That freedom appears to have sped up the closures. Company leadership has pointed to shrinking pharmacy reimbursement rates (the fees health insurers and benefit managers pay pharmacies to dispense drugs), weaker retail foot traffic, and competition from Amazon Pharmacy as the reasons roughly a quarter of stores no longer fit the strategy.

As Motz put it in a company statement: "As a private organization, alongside our dedicated team members, we are renewing our focus on our core pharmacy and retail platform, our stores and our customer experience." In practice, focusing means choosing which stores survive.

Why your prescriptions probably end up at CVS

Here is the mechanism that most people never see. Federal and state rules require an orderly transfer of prescription records when a pharmacy closes. In many markets, those records land at the nearest CVS, because Walgreens and CVS spent decades planting stores within a mile or two of each other across the same suburbs. The competitive strategy that once drove both chains to cluster together is now handing CVS a quiet windfall.

CVS doesn't need a price war or an ad campaign. It just needs to be open.

The combined numbers show how sticky this has become. CVS and Walgreens together now handle nearly 40 percent of all U.S. retail prescription sales, even as both companies shrink their total store counts. Consolidation is increasing market concentration even during retreat.

CVS also has a structural advantage that Walgreens never fully matched. Its ownership of Caremark, one of the three dominant pharmacy benefit managers in the country, gives CVS control over a piece of the supply chain that decides reimbursement rates in the first place. When reimbursement pressure squeezes retail pharmacies, CVS can absorb some of that hit internally in ways a pure retail operator cannot. Walgreens was on the wrong side of that equation.

What this means for you

If you live near a closing Walgreens, the immediate inconvenience is real but manageable: a new location, a new app, a pharmacist who doesn't know your name yet. The deeper issue takes longer to feel.

When two chains already handle 40 percent of prescription volume and one of them consolidates around fewer, stronger locations, the remaining stores carry more leverage. Less competition means less pressure to compete on wait times, staffing levels, or price on the things you pay for out of pocket.

For rural and lower-income suburban areas, the math gets harder faster. These are often the markets where both chains already ran thin, and where an independent pharmacy is not waiting a mile away to absorb the overflow. When the Walgreens closes there, the nearest open pharmacy may not be close at all.

The private equity ownership adds one more layer of uncertainty. Sycamore's interest is in restructuring Walgreens into something profitable enough to eventually sell or take public again. The stores that survive will be the ones that serve that goal. The communities around the ones that don't have little say in the matter.